Product Images Dabigatran Etexilate

This is not-available.*

This is a description of Dabigatran Etexilate Capsules provided by Aurobindo Pharma USA, Inc. Each pack contains 60 capsules in 10 blister cards with 6 capsules each. The capsules contain 110 mg of dabigatran etexilate equivalent to 830 mg of dabigatran efexlate mesylate. The usual dosage instructions and storage conditions are provided in the medication guide included separately with each pack. It is advised to store the capsules at 20°C to 25°C with excursions permitted to 15°C to 30°C. The product is distributed in the USA and manufactured in India. Keep out of reach of children and store in the original package to protect from moisture.*

The text is not readable.*

This text provides information about the time course of aPTT (Activated Partial Thromboplastin Time) for a patient receiving Dabigatran Etexilate, with different dose recommendations depending on the patient's creatinine clearance rate. A dose of 150 mg BID is advised when the creatinine clearance is above 30 mL/min, and 75 mg BID when it is below that value. Additionally, the chart shows the aPTT levels for different creatinine clearance thresholds, such as above 50 and 80 mL/min. It also refers to the time in hours for the assessment.*

This text appears to be a list of interacting drugs, doses, and time differences, along with pharmacokinetic parameters such as AUC and Cmax. It seems to also mention fold change and 90% confidence intervals. The text might be used for evaluating drug interactions and their effects on pharmacokinetics.*

This text provides details about the medication "Dabigatran Etexilate Capsules" with a concentration of 75mg per capsule. The capsules are non-substitutable with other forms of dabigatran etexilate on a milligram-to-milligram basis. The text instructs to swallow the capsules whole and mentions the importance of using the product within 4 months once opened. The manufacturer is Aurobindo Pharma USA, Inc., and the medication is made in India. The usual dosage information is available in the package insert. Storage instructions recommend storing at 20° to 25°C with excursions permitted between 15° to 30°C. The text also indicates that the medication guides can be accessed online.*

This is a detailed description of Dabigatran Etexilate Capsules containing 75 mg of dabigatran etexilate equivalent to 86.475 mg of dabigatran etexilate mesylate. The capsules are not interchangeable with other forms of dabigatran etexilate on a mg-to-mg basis. Patients are instructed to swallow the capsules whole. Each pack contains 60 capsules arranged in 10 blister cards with 6 capsules each. The recommended storage conditions are between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). It is advised to store the medication in the original package to protect it from moisture and keep it out of reach of children. The medication guide is provided separately to each patient, with more information available at the manufacturer's website. The product is made in India and the NDC number is 59651-973-61.*

This text provides important information about Dabigatran Etexilate capsules, including dosage instructions, storage guidelines, and contact information for the manufacturer. It emphasizes the necessity to swallow the capsule whole, use the product within 4 months of opening, and clarifies that the capsules are not interchangeable with other forms of dabigatran etexilate on a milligram-to-milligram basis. The text also specifies the content of each capsule, usual dosage recommendations, and details about storage temperature requirements. Furthermore, it includes a reference to the manufacturer's Medication Guides website and indicates the manufacturing location in India.*